Aminoesters of rapamycin

Abstract

A compound of the structure ##STR1## wherein R 1 and R 2 are each, independently, hydrogen or ##STR2## with the proviso that R 1 and R 2 are not both hydrogen; R 3 is hydrogen, alkyl, aralkyl, --(CH 2 ) q CO 2 R 6 ,--(CH 2 ) r NR 7 CO 2 R 8 , carbamylalkyl, aminoalkyl, hydroxyalkyl, guanylalkyl, mercaptoalkyl, alkylthioalkyl, indolylmethyl, hydroxyphenyklmethyl, imidazoylmethyl or phenyl which is optionally mono-, di-, or tri-substituted with a sustituent selected from alkyl, alkoxy, hydroxy, cyano, halo, nitro, carbalkoxy, trifluoromethyl, amino, or a carboxylic acid; R 4 and R 7 are each, independently, hydrogen, alkyl, or aralkyl; R 5 , R 6 , and R 8 are each, indpendently, alkyl, aralkyl, fluorenylmethyl, or phenyl which is optionally mono-, di-, or tri-substituted with a substituent selected from alkyl, alkoxy, hydroxy, cyano, halo, nitro, carbalkoxy, trifluoromethyl, amino, or a carboxylic acid; m is 0-4; n is 0-4; p is 1-2; q is 0-4; r is 0-4; wherein R 3 , R 4 , m, and n are independent in each of the ##STR3## subunits when p=2; or a pharmaceutically acceptable salt thereof, which by virtue of its immunosuppressive activity is useful in treating transplantation rejection, host vs. graft disease, autoimmune diseases, and diseases of inflammation, and by virtue of its antifungal activity is useful in treating fungal infections.

Claims

What is claimed is: 1. A compound of the formula ##STR8## wherein R 1 and R 2 are each, independently, hydrogen or ##STR9## with the proviso that R 1 and R 2 are not both hydrogen; R 3 is hydrogen, alkyl of 1-6 carbon atoms, phenylalkyl of 7-10 carbon atoms, --(CH 2 ) q CO 2 R 6 , --(CH 2 ) r NR 7 CO 2 R 8 , carbamylalkyl of 2-3 carbon atoms, aminoalkyl of 1-4 carbon atoms, hydroxyalkyl of 1-4 carbon atoms, guanylalkyl of 2-4 carbon atoms, mercaptoalkyl of 1-4 carbon atoms, alkylthioalkyl of 2-6 carbon atoms, indolylmethyl, hydroxyphenylmethyl, imidazolylmethyl or phenyl which is optionally mono-, di-, or tri-substituted with a substitutent selected from alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, or --CO 2 H, R 4 and R 7 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, or phenylaklyl of 7-10 carbon atoms; R 5 , R 6 , and R 8 are each, independently, alkyl of 1-6 carbon atoms, phenylalk of 7-10 carbon atoms, fluorenylmethyl, or phenyl which is optionally mono-, di-, or tri-substituted with a substituent selected from alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, or --CO 2 H; m is 0-4; n is 0-4; p is 1-2; q is 0-4; r is 0-4; wherein R 3 , R 4 , m, and n are independent in each of the ##STR10## subunits when p=2; or a pharmaceutically acceptable salt thereof. 2. A compound of claim 1 where m=0, n=0, and p=1 or a pharmaceutically acceptable salt thereof. 3. A compound of claim 1 where m=0, n=0, and p=2 or a pharmaceutically acceptable salt thereof. 4. A compound of claim 1 where n=0, and R 3 is --(CH 2 ) q CO 2 R 6 or a pharmaceutically acceptable salt thereof. 5. A compound of claim 1 where m=0, n=0, and R 3 is --(CH 2 ) r NR 7 CO 2 R 8 or a pharmaceutically acceptable salt thereof. 6. A compound of claim 1 where m=0, n=0, and R 3 is hydrogen or a pharmaceutically acceptable salt thereof. 7. A compound of claim 1 which is rapamycin-42-ester with N-[(1,1-dimethylethoxy)carbonyl]-glycylglycine or a pharmaceutically acceptable salt thereof. 8. A compound of claim 1 which is rapamycin-31,42-diester with N-[(1,1-dimethyl-ethoxy)carbonyl]-glycylglycine or a pharmaceutically acceptable salt thereof. 9. A compound of claim 1 which is rapamycin-31,42-diester with N-[(1,1-dimethylethoxy)carbonyl]-N-methylglycine or a pharmaceutically acceptable salt thereof. 10. A compound of claim 1 which is rapamycin-42-ester with N-[(1,1-dimethylethoxy)carbonyl]-N-methylglycine or a pharmaceutically acceptable salt thereof. 11. A compound of claim 1 which is rapamycin-31,42-diester with 5-(1,1-dimethylethoxy)-2-[[(1,1-dimethylethoxy)carbonyl]amino]-5-oxopentanoic acid or a pharmaceutically acceptable salt thereof. 12. A compound of claim 1 which is rapamycin-42-ester with 5-(1,1-dimethylethoxy)-2- [[(1,1-dimethylethoxy)carbonyl]amino]-5-oxopentanoic acid or a pharmaceutically acceptable salt thereof. 13. A compound of claim 1 which is rapamycin-31,42-diester with 2-[[(1,1-dimethylethoxy)carbonyl]amino]-4-oxo-4-(phenylmethoxy) butanoic acid or a pharmaceutically acceptable salt thereof. 14. A compound of claim 1 which is rapamycin-31,42-diester with 3-[[(1,1-dimethylethoxy)carbonyl]amino]-4-oxo-4-(phenylmethoxy) butanoic acid or a pharmaceutically acceptable salt thereof. 15. A compound of claim 1 which is rapamycin-42-ester with 3-[[(1,1-dimethylethoxy)carbonyl]amino]-4-oxo-4-(phenylmethoxy) butanoic acid or a pharmaceutically acceptable salt thereof. 16. A compound of claim 1 which is rapamycin-42-ester with 5-(1,1-dimethyloxy)-4-[[(1,1-dimethylethoxy)carbonyl]amino]-5-oxopentanoic acid or a pharmaceutically acceptable salt thereof. 17. A compound of claim 1 which is rapamycin-31,42-diester with 5-(1,1-dimethylethoxy)-4-[[(1,1-dimethylethoxy)carbonyl]amino]-5-oxopentanoic acid or a pharmaceutically acceptable salt thereof. 18. A compound of claim 1 which is rapamycin-42-ester with N.sup.α, N.sup.ε -bis[(1,1-dimethylethoxy)carbonyl]-L-lysine or a pharmaceutically acceptable salt thereof. 19. A compound of claim 1 which is rapamycin-31,42-diester with N.sup.α, N.sup.ε bis[(1,1-dimethylethoxy)carbonyl]-L-lysine or a pharmaceutically acceptable salt thereof. 20. A method of treating transplantation rejection, host vs. graft disease, autoimmune diseases, and diseases of inflammation in a mammal by administering an effective amount of a compound having the formula ##STR11## wherein R 1 and R 2 are each, independently, hydrogen or ##STR12## with the proviso that R 1 and R 2 are not both hydrogen; R 3 is hydrogen, alkyl of 1-6 carbon atoms, phenylalkyl of 7-10 carbon atoms, --(CH 2 ) q CO 2 R 6 , --(CH 2 ) r NR 7 CO 2 R 8 , carbamylalkyl of 2-3 carbon atoms, aminoalkyl of 1-4 carbon atoms, hydroxyalkyl of 1-4 carbon atoms, guanylalkyl of 2-4 carbon atoms, mercaptoalkyl of 1-4 carbon atoms, alkylthioalkyl of 2-6 carbon atoms, indolylmethyl, hydroxyphenylmethyl, imidazoylmethyl or phenyl which is optionally mono-, di-, or tri-substituted with a substituent selected from alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, or --CO 2 H; R 4 and R 7 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, or phenylalkyl of 7-10 carbon atoms; R 5 , R 6 , and R 8 are each, independently, alkyl of 1-6 carbon atoms, phenylalkyl of 7-10 carbon atoms, fluorenylmethyl, or phenyl which is optionally mono-, di-, or trisubstituted with a substituent with a substituent selected from alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, or --CO 2 H; m is 0-4; n is 0-4; p is 1-2; q is 0-4; r is 0-4; wherein R 3 , R 4 , m, and n are independent in each of the ##STR13## subunits when p=2; or a pharmaceutically acceptable salt thereof. 21. A pharmaceutical composition for use as an immunosuppressive agent comprising an immunosuppressive amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof. 22. A composition in claim 21 in unit dosage form.
This is a continuation in part of application Ser. No. 07/589,878, filed Sep. 28, 1990. BACKGROUND OF THE INVENTION This invention relates to novel esters of rapamycin and a method for using them in the treatment of transplantation rejection, host vs. graft disease, autoimmune diseases, diseases of inflammation, and fungal infections. Rapamycin is a macrocyclic triene antibiotic produced by Streptomyces hygroscopicus, which was found to have antifungal activity, particularly against Candida albicans, both in vitro and in vivo [C. Vezina et al., J. Antibiot. 28, 721 (1975); S. N. Seghal et al., J. Antibiot. 28, 727 (1975); H. A. Baker et al., J. Antibiot. 31, 539 (1978); U.S. Pat. No. 3,929,992; and U.S. Pat. No. 3,993,749]. Rapamycin alone (U.S. Pat. No. 4,885,171) or in combination with picibanil (U.S. Pat. No. 4,401,653) has been shown to have antitumor activity. R. Martel et al. [Can. J. Physiol. Pharmacol. 55, 48 (1977)] disclosed that rapamycin is effective in the experimental allergic encephalomyelitis model, a model for multiple sclerosis; in the adjuvant arthritis model, a model for rheumatoid arthritis; and effectively inhibited the formation of IgE-like antibodies. The immunosuppressive effects of rapamycin have been disclosed in FASEB 3, 3411 (1989), rapamycin has been shown to be effective in inhibiting transplant rejection (U.S. patent application Ser. No. 362,544 filed Jun. 6, 1989). Cyclosporin A and FK-506, other macrocyclic molecules, also have been shown to be effective as immunosuppressive agents, therefore useful in preventing transplant rejection [FASEB 3, 3411 (1989); FASEB 3, 5256 (1989); and R. Y. Calne et al., Lancet 1183 (1978)]. Mono- and diacylated derivatives or rapamycin (esterified at the 28 and 43 positions) have been shown to be useful as antifungal agents (U.S. Pat. No. 4,316,885) and used to make water soluble prodrugs of rapamycin (U.S. Pat. No. 4,650,803). Recently, the numbering convention for rapamycin has been changed; therefore according to Chemical Abstracts nomenclature, the esters described above would be at the 31- and 42-positions. DESCRIPTION OF THE INVENTION This invention provides derivatives of rapamycin which are useful as immunosuppressive, anti-inflammatory, and antifungal agents having the structure ##STR4## wherein R 1 and R 2 are each, independently, hydrogen or ##STR5## with the proviso that R 1 and R 2 are not both hydrogen; R 3 is hydrogen, alkyl of 1-6 carbon atoms, aralkyl of 7-10 carbon atoms, --(CH 2 ) q CO 2 R 6 , --(CH 2 ) r NR 7 CO 2 R 8 , carbamylalkyl of 2-3 carbon atoms, aminoalkyl of 1-4 carbon atoms, hydroxyalkyl of 1-4 carbon atoms, guanylalkyl of 2-4 carbon atoms, mercaptoalkyl of 1-4 carbon atoms, alkylthioalkyl of 2-6 carbon atoms, indolylmethyl, hydroxyphenylmethyl, imidazoylmethyl or phenyl which is optionally mono-, di-, or tri-substituted with a substituent selected from alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, or a carboxylic acid; R 4 and R 7 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, or aralkyl of 7-10 carbon atoms; R 5 , R 6 , and R 8 are each, independently, alkyl of 1-6 carbon atoms, aralkyl of 7-10 carbon atoms, fluorenylmethyl, or phenyl which is optionally mono-, di-, or tri-substituted with a substituent selected from alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, or a carboxylic acid; m is 0-4; n is 0-4; p is 1-2; q is 0-4; r is 0-4; wherein R 3 , R 4 , m, and n are independent in each of the ##STR6## subunits when p=2; or a pharmaceutically acceptable salt thereof. Of the compounds, preferred members are those in which m=0, n=0, and p=1; m=0, n=0, and p=2; n=0, and R 3 is --(CH 2 ) q CO 2 R 6 ; m=0, n=0, and R 3 is --(CH 2 ) r NR 7 CO 2 R 8 ; and m=0, n=0, and R 3 is hydrogen. The pharmaceutically acceptable salts may be formed from inorganic cations such as sodium, potassium, and the like and organic acids such as, acetic, lactic, citric, tartaric, succinic, maleic, malonic, gluconic, and the like, when R 3 contains a basic amino group. The compounds of this invention can be prepared by acylating rapamycin with an acylating agent having the general structure ##STR7## where X is OH in the presence of a coupling reagent, such as dicyclohexylcarbodiimide. The compounds of this invention also can be prepared using a mixed anhydride of the above described carboxylic acid as the acylating species. Alternatively, the acylating species can be an acid halide, where X can be Cl, Br, or I. The acylating groups used to prepare the compounds of this invention are commercially available or can be prepared by methods that are disclosed in the literature. Immunosuppressive activity was evaluated in an in vitro standard pharmacological test procedure to measure lymphocyte proliferation (LAF) and in two in vivo standard pharmacological test procedures. The first in vivo procedure was a popliteal lymph node (PLN) test procedure which measured the effect of compounds of this invention on a mixed lymphocyte reaction and the second in vivo procedure evaluated the survival time of a pinch skin graft. The comitogen-induced thymocyte proliferation procedure (LAF) was used as an in vitro measure of the immunosuppressive effects of representative compounds. Briefly, cells from the thymus of normal BALB/c mice are cultured for 72 hours with PHA and IL-1 and pulsed with tritiated thymidine during the last six hours. Cells are cultured with and without various concentrations of rapamycin, cyclosporin A, or test compound. Cells are harvested and incorporated; radioactivity is determined. Inhibition of lymphoproliferation is assessed in percent change in counts per minute from non-drug treated controls. The results are expressed by the following ratio, or as the percent inhibition of lymphoproliferation of 1 μM. ##EQU1## A mixed lymphocyte reaction (MLR) occurs when lymphoid cells from genetically distinct animals are combined in tissue culture. Each stimulates the other to undergo blast transformation which results in increased DNA synthesis that can be quantified by the incorporation of tritiated thymidine. Since stimulating a MLR is a function of disparity at Major Histocompatibility antigens, an in vivo popliteal lymph node (PLN) test procedure closely correlates to host vs. graft disease. Briefly, irradiated spleen cells from BALB/c donors are injected into the right hind foot pad of recipient C3H mice. The drug is given daily, p.o. from Day 0 to Day 4. On Day 3 and Day 4, tritiated thymidine is given i.p., b.i.d. On Day 5, the hind popliteal lymph nodes are removed and dissolved, and radioactivity counted. The corresponding left PLN serves as the control for the PLN from the injected hind foot. Percent suppression is calculated using the non-drug treated animals as allogenic control. Rapamycin at a dose of 6 mg/kg, p.o. gave 86% suppression, whereas cyclosporin A at the same dose gave 43% suppression. Results are expressed by the following ratio: ##EQU2## The second in vivo test procedure is designed to determine the survival time of pinch skin graft from male DBA/2 donors transplanted to male BALB/c recipients. The method is adapted from Billingham R.E. and Medawar P.B., J. Exp. Biol. 28:385-402, (1951). Briefly, a pinch skin graft from the donor is grafted on the dorsum of the recipient as a homograft, and an autograft is used as control in the same region. The recipients are treated with either varying concentrations of cyclosporin A as test control or the test compound, intraperitoneally. Untreated recipients serve as rejection control. The graft is monitored daily and observations are recorded until the graft becomes dry and forms a blackened scab. This is considered as the rejection day. The mean graft survival time (number of days ±S.D.) of the drug treatment group is compared with the control group. The following table summarizes the results of representative compounds of this invention in these three standard test procedures. TABLE 1______________________________________ LAF* PLN* Skin GraftCompound (ratio) (ratio) (days + SD)______________________________________Example 1 1.8 0.61 12.0 ± 1.6Example 2 0.33 0.62 11.5 ± 0.6Example 3 0.20 + 9.0 ± 0.9Example 4 4.9 0.18 12.3 ± 0.5Example 5 0.006 + 8.8 ± 0.9Example 6 5.4 0.33 11.5 ± 3.5Example 7 3% at 1 μM** + 7.7 ± 1.5Example 8 0.03 0.41 +Example 9 0.96 1.34 10.3 ± 0.8Example 10 2.0 .sup. 0.96.sup.++ 12.7 ± 1.2Example 11 0.004 + 10.5 ± 1.3Example 12 19.8 -2.87 12.0 ± 2.0Example 13 22% at 1 μM** + 7.0 ± 0.6Rapamycin 1.0 1.0 12.0 ± 1.7______________________________________ *Calculation of ratios was described supra. **Result expressed as percent inhibition of lymphoproliferation at 1 μM. + Not evaluated. .sup.++ Results obtained using cremophore/ethanol as a vehicle for administration. Ratios of 0.33 and 1.07 were also obtained using carboxymethyl cellulose as a vehicle for administration. The results of these standard pharmacological test procedures demonstrate immunosuppressive activity both in vitro and in vivo for the compounds of this invention. Positive ratios in the LAF and PLN test procedures indicate suppression of T cell proliferation. As a transplanted pinch skin grafts are typically rejected within 6-7 days without the use of an immunosuppressive agent, the increased survival time of the skin graft when treated with the compounds of this invention further demonstrates their utility as immunosuppressive agents. While it appears that the compound disclosed by Example 12 may cause T cell proliferation in the PLN test procedure, it is believed a negative ratio in this test procedure coupled with an increased survival time observed in the skin graft test procedure indicates a proliferation of T suppressor cells, which are implicated in suppressing the immune response. (see, I. Roitt et al. Immunology, C. V. Moseby Co. 1989, p 12.8-12.11). Antifungal activity of the compounds of this invention was measured against 5 strains of Candida albicans using a plate test procedure for measurement of inhibition. The following represents the typical procedure used. Compound to be tested was placed on sterile dried 1/4" plate disks, and allowed to dry. Agar plates were seeded with fungi and allowed to solidify. The impregnated disks were placed on the seeded Agar surface and incubated for the time required for the particular culture. Results are expressed in MIC (μg/ml) to inhibit growth. The results of this test procedure showed that the compounds of this invention have antifungal activity; however, it was surprising that the compounds of this invention were less active than the parent compound, rapamycin. TABLE 2*______________________________________Strain of Candida albicans ATCC ATCC ATCC ATCCCompound 10231 38246 38247 38248 3669______________________________________Example 1 >0.4 >0.4 >0.4 >0.4 >0.4Example 2 0.1 0.2 0.2 0.2 0.1Example 3 0.4 >0.4 >0.4 >0.4 0.4Example 4 0.1 0.4 0.1 0.1 0.2Example 5 >0.4 >0.4 >0.4 >0.4 >0.4Example 6 0.1 >0.4 0.2 0.4 >0.4Example 7 + + + + +Example 8 >0.4 >0.4 >0.4 >0.4 >0.4Example 9 0.4 >0.4 0.4 >0.4 >0.4Example 10 0.2 >0.4 0.2 0.4 0.4Example 11 >0.4 >0.4 >0.4 >0.4 >0.4Example 12 0.2 >0.4 0.1 0.2 0.4Example 13 >0.4 >0.4 >0.4 >0.4 >0.4Rapamycin 0.003 0.025 0.003 0.006 0.025______________________________________ *expressed as MIC (μg/ml) + not evaluated Based on the results of these standard pharmacological test procedures, the compounds are useful in the treatment of transplantation rejection such as, heart, kidney, liver, bone marrow, and skin transplants; autoimmune diseases such as, lupus, rheumatoid arthritis, diabetes mellitus, myasthenia gravis, and multiple sclerosis; and diseases of inflammation such as, psoriasis, dermatitis, eczema, seborrhea, inflammatory bowel disease; and fungal infections. The compounds may be administered neat or with a pharmaceutical carrier to a mammal in need thereof. The pharmaceutical carrier may be solid or liquid. A solid carrier can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents; it can also be an encapsulating material. In powders, the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets, the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain up to 99% of the active ingredient. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins. Liquid carriers are used in preparing solutions, suspensions, emulsions, syrups, elixirs and pressurized compositions. The active ingredient can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats. The liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (partially containing additives as above, e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g. glycols) and their derivatives, and oils (e.g. fractionated coconut oil and arachis oil). For parenteral administration, the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are useful in sterile liquid form compositions for parenteral administration. The liquid carrier for pressurized compositions can be halogenated hydrocarbon or other pharmaceutically acceptable propellent. Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. The compound can also be administered orally either in liquid or solid composition form. Preferably, the pharmaceutical composition is in unit dosage form, e.g. as tablets or capsules. In such form, the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient; the unit dosage forms can be packaged compositions, for example, packeted powders, vials, ampoules, prefilled syringes or sachets containing liquids. The unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form. The dosage to be used in the treatment must be subjectively determined by the attending physician. In addition, the compounds of this invention may be employed as a solution, cream, or lotion by formulation with pharmaceutically acceptable vehicles containing 0.1-0.5 percent, preferably 2%, of active compound which may be administered to a fungally affected area. The following examples illustrate the preparation of representative compounds of this invention. EXAMPLE 1 Rapamycin-42-ester with N-[(1,1-dimethylethoxy)carbonyl]-glycylglycine Under anhydrous conditions, a solution of rapamycin (3 g, 3.28 mmole) and N-[(1,1-dimethylethoxy)carbonyl]-glycylglycine (3.04 g, 13.1 mmole) in 40 mL of anhydrous dichloromethane was treated with dicyclohexylcarbodiimide (1.35 g, 6.56 mmole) followed by 4-dimethylaminopyridine (0.8 g, 6.56 mmole). After stirring at ambient temperature for 48 hours, the precipitated solid was collected and washed with dichloromethane. The combined filtrates were absorbed directly onto silica gel Merck 60 by adding the gel and evaporation to dryness. Flash chromatography of the preabsorbed material (using a gradient elution with ethylacetate-toluene from 2:1 to 1:0 v/v) afforded 1.05 g (28.3%) of the title compound isolated as a three quarter toluene solvate, along with the 31,42-diester of Example 2. HPLC analysis showed that the monoester is a 8.3:1 mixture of two conformers. 1 H NMR (CDCl 3 , 400 MHz): δ1.46 (m, 9H, COOBu t ), 1.654 (s, 3H, CH 3 C═C), 1.751 (s, 3H, CH 3 C═C), 3.14 (s, 3H, CH 3 O), 3.33 (s, 3H, CH 3 O), 3.36 (s, 3H, CH 3 O), 4.18 (d, 1H, CHOH), 4.75 (m, 1H, 42-CHO), 4.79 (s, 1H, OH); High Res. MS (neg. ion FAB) Calcd for C 60 H 93 N 3 O 17 : 1127.6504, measured mass 11.27.6474. Anal. Calcd for C 60 H 93 N 3 O 17 .0.75 PhCH 3 : C, 65.45; H, 8.33; N, 3.51; Found: C, 65,23; H, 8.32; N, 3.86. The following representative compounds can be prepared from rapamycin and the appropriate terminally-N-substituted amino acid by employing the method used to prepare the title compound in Example 1. Rapamycin-42-ester with N-[(fluorenylmethoxy)carbonyl]-alanylserine Rapamycin-42-ester with N-[(fluorenylmethoxy)carbonyl]-glycylglycine Rapamycin-42-ester with N-[(ethoxy)carbonyl]-arginylmethionine Rapamycin-42-ester with N-[(4'-chlorophenoxy)carbonyl]-histidylarginine Rapamycin-42-ester with N-[(phenoxy)carbonyl]-tryptophanylleucine Rapamycin-42-ester with N-[(phenylmethoxy)carbonyl]-N-methylglycyl-N-ethylalanine Rapamycin-42-ester with N-[(phenylmethoxy)carbonyl]-N-methyl-β-alanylphenylalanine Rapamycin-42-ester with N-[(1,1-dimethylethoxy)carbonyl]-cysteinylglycine EXAMPLE 2 Rapamycin-31,42-diester with N-[(1,1-dimethylethoxy)carbonyl]-glycylglycine The title compound (1.85 g, 42%) was separated from the 42-monoester as described in Example 1 and isolated as a three quarter toluene solvate. HPLC analysis showed that the diester is a 8.1:1 mixture of conformers. 1 H NMR (CDCl 3 , 400 MHz): δ1.452 (m, 18H, COOBu t ), 1.6612 (s, 3H, CH 3 C═C), 1.7815 (s, 3H, CH 3 C═C), 3.14 (s, 3H, OCH 3 ), 3.34 (s, 3H, OCH 3 ), 3.35 (s, 3H, OCH 3 ), 4.52 (s, 1H, OH), 4.79 (m, 1H, 42-CHO); High Res. MS (neg. ion FAB): Calcd for C 69 H 107 N 5 O 21 1341.7458, measured mass: 1341.7463. Anal. Calcd for C 69 H 107 N 5 O 21 .0.75 PhCH 3 : C, 63.17; H, 8.06; N, 4.96; Found: C, 62.83; H, 8.09; N, 5.00. The following representative compounds can be prepared from rapamycin and the appropriate terminally-N-substituted amino acid by employing the method used to prepare the title compound in Example 2. Rapamycin-31,42-diester with N-[(fluorenylmethoxy)carbonyl]-alanylserine Rapamycin-31,42-diester with N-[(fluorenylmethoxy)carbonyl]-glycylglycine Rapamycin-31,42-diester with N-[(ethoxy)carbonyl]-arginylmethionine Rapamycin-31,42-diester with N-[(4'-chlorophenoxy)carbonyl]-histidylarginine Rapamycin-31,42-diester with N-[(phenoxy)carbonyl]-tryptophanylleucine Rapamycin-31,42-diester with N-[(phenylmethoxy)carbonyl)]-N-methylglycyl-N-ethyl-alanine Rapamycin-31,42-diester with N-[(phenylmethoxy)carbonyl]-N-methyl-β-alanylphenyl-alanine Rapamycin-31,42-diester with N-[(1,1-dimethylethoxy)carbonyl]-cysteinylglycine EXAMPLE 3 Rapamycin-31,42-diester with N-[(1,1-dimethylethoxy)carbonyl]-N-methylglycine Under anhydrous conditions, an ice cold solution of rapamycin (2 g, 2.18 mmole) and N.sup.α -Boc sarcosine (1.65 g, 8.75 mmole) in 20 ml of anhydrous dichloromethane was treated with dicyclohexylcarbodiimide (1.8 g, 8.7 mmole) followed by 4-dimethylaminopyridine (1 g, 8.7 mmole). After stirring overnight at ambient temperature, the precipitated solid was collected and washed with dichloromethane. The combined filtrates were evaporated to dryness to give an amorphous amber solid (3 g). The crude product was purified by flash chromatography (on silica Merck 60, elution with hexane-ethylacetate 1:1, v/v) to provide the title compound (0.75 g, 27.4%) along with the 42-monoester of Example 4. HPLC analysis showed that the diester is a 19.8:1 mixture of two conformers. The multiplicity of the NMR peaks suggests the presence of amide rotamers. 1 H NMR (CDCl 3 , 400 MHz): δ1.411, 1.438, 1.448 and 1.474 (m, 18H, COOBu t ), 2.91 (m, 6H, NCH 3 ), 3.14 (s, 3H, CH 3 O), 3.34 (s, 3H, CH 3 O), 3.37 (s, 3H, CH 3 O), 4.73 (broad, 1H, 42-CHO), 4.82 (2s, 1H, OH); High Res. MS (neg. ion FAB): Calcd. for C 67 H 105 N 3 O 19 1255.7342, measured mass 1255.7289. Anal. Calcd for C 67 H 105 N 3 O 19 : C, 64.04; H, 8.42; N, 3.34; Found: C, 64.14; H, 8.74; N, 3.63. The following representative compounds can be prepared from rapamycin and the appropriate terminally-N-substituted amino acid by employing the method used to prepare the title compound in Example 3. Rapamycin-31,42-diester with N-[(ethoxy)carbonyl]-tyrosine Rapamycin-31,42-diester with N-[(fluorenylmethoxy)carbonyl]-phenylalanine Rapamycin-31,42-diester with N-[(3',4',5'-trihydroxyphenoxy)carbonyl]-isoleucine Rapamycin-31,42-diester with N-[(1,1-dimethylethoxy)carbonyl)-glutamine Rapamycin-31,42-diester with N-[(phenoxy)carbonyl]-N-methylalanine Rapamycin-31,42-diester with N-[(propyloxy)carbonyl]-4-aminobutryic acid Rapamycin-31,42-diester with N-[(phenylmethoxy)carbonyl]-7-aminoheptanoic acid Rapamycin-31,42-diester with N-[(fluorenylmethoxy)carbonyl]-serine EXAMPLE 4 Rapamycin-42-ester with N-[(1,1-dimethylethoxy)carbonyl]-N-methylglycine Under anhydrous conditions, an ice cold solution of rapamycin (0.95 g, 1.02 mmole) and N.sup.α -Boc sarcosine (0.21 g, 1.1 mmole) in 20 mL of anhydrous dichloromethane was treated with dicyclohexylcarbodiimide 0.21 g, 1 mmole) followed by 4-dimethylaminopyridine (0.12 g, 1 mmole). After stirring for 4 hours at ambient temperature, the precipitated solid was collected and washed with dichloromethane. The combined filtrates were concentrated in vacuo to give an amorphous amber solid. Flash chromatography of the crude product (on silica Merck 60, elution with hexaneethylacetate 1:1 v/v to remove the diester of Example 3, followed by chloroformethylacetate-methanol 75:25:1 v/v) provided partially purified title compound (0.38 g, 35%). Pure product was obtained by preparative HPLC (Waters Prep 500, silica gel, chloroform-ethylacetate-methanol 75:25:1 v/v, flow rate 250 mL/min). HPLC analysis showed that the ester is a 6.6:1 mixture of two conformers. The multiplicity of NMR peaks suggests the presence of amide rotamers. 1 H NMR (CDCl 3 , 400 MHz): δ1.42-1.46 (ds, 9H, COOBu t ), 2.91 (ds, 3H, NCH 3 ), 1.644 (s, 3H, CH 3 C═C), 1.738 (s, 3H, CH 3 C═C), 3.12 (s, 3H, CH 3 O), 3.32 (s, 3H, CH 3 O), 3.35 (s, 3H, CH 3 O), 4.18 (d, 1H, CHOH), 4.71 (broad, 1H, 42-CHO), 4.78 (broad s, 1H, OH); High Res. MS (neg. ion FAB): Calcd for C 59 H 92 N 2 O 16 1084.6446, measured mass 1084.6503. Anal. Calcd for C 59 H 92 N 2 O 16 : C, 65.29; H, 8.54; N, 2.58; Found: C, 65.25; H, 8.52; N, 2.42. The following representative compounds can be prepared from rapamycin and the appropriate terminally-N-substituted amino acid by employing the method used to prepare the title compound in Example 4. Rapamycin-42-ester with N-[(ethoxy)carbonyl]-tyrosine Rapamycin-42-ester with N-[(fluorenylmethoxy)carbonyl]-phenylalanine Rapamycin-42-ester with N-[(3',4',5'-trihydroxyphenoxy)carbonyl]-isoleucine Rapamycin-42-ester with N-[(1,1-dimethylethoxy)carbonyl)-glutamine Rapamycin-42-ester with N-[(phenoxy)carbonyl]-N-methylalanine Rapamycin-42-ester with N-[(propyloxy)carbonyl]-4-aminobutryic acid Rapamycin-42-ester with N-[(phenylmethoxy)carbonyl]-7-aminoheptanoic acid Rapamycin-31,42-diester with N-[(fluorenylmethoxy)carbonyl]serine EXAMPLE 5 Rapamycin-31,42-diester with 5-(1,1-dimethylethoxy)-2-[[(1,1-dimethylethoxy)carbonyl]amino]-5-oxopentanoic acid Under anhydrous conditions, an ice cold solution of rapamycin (4 g, 4.37 mmole) and L-glutamic acid N.sup.α -Boc-γ-tert-butylester (4.9 g, 16.1 mmole) in 40 mL of dry dichloromethane was treated with dicyclohexylcarbodiimide (1.8 g, 8.7 mmole) followed by 4-dimethylaminopyridine (1 g, 8.7 mmole). After stirring overnight at room temperature, the precipitated solid was collected and washed with dichloromethane. The combined filtrates were concentrated in vacuo to provide 11 g of an amorphous amber solid. The crude product was purified by flash chromatography (on silica Merck 60, gradient elution with hexane-ethylacetate from 2:1 to 1:1, v/v) to yield 4.52 g (69.6%) of the title compound along with the 42-monoester of Example 6. HPLC analysis showed that the diester consists of a 6.6:1 mixture of two conformers. 1 H NMR (CDCl 3 , 400 MHz): δ1.42 (m, 36H, COOBu t ), 1.646 (s, 3H, CH 3 C═C), 1.701 (s, 3H, CH 3 C═C), 3.13 (s, 3H, CH 3 O), 3.34 (s, 3H, CH 3 O), 3.36 (s, 3H, CH 3 O), 4.735 (m, 2H, OH+42-CH--O); High Res. MS (neg. ion FAB): calc. for C 79 H 125 N 3 O 23 1483.8715, measured mass 1483.8714. Anal. Calcd for C 79 H 125 N 3 O 23 : C, 63.90; H, 8.49; N, 2.83; Found: C, 63.63; H, 8.41; N, 2.44. The following representative compounds can be prepared from rapamycin and the appropriately terminally-N-substituted amino diacid monoester by employing the method used to prepare the title compound in Example 5. Rapamycin-31,42-diester with 6-(phenylmethoxy)-2-[[fluorenylmethoxy)carbonyl]amino]-6-oxohexanoic acid Rapamycin-31,42-diester with 6-(4'-methylphenoxy)-3-[[(phenylmethoxy)carbonyl]amino-6-oxohexanoic acid Rapamycin-31,42-diester with 6-(ethoxy)-4-[[(phenoxy)carbonyl]amino]-6-oxohexanoic acid Rapamycin-31,42-diester with 6-(methoxy)-5-[[(ethoxy)carbonyl]amino]-6-oxohexanoic acid Rapamycin-31,42-diester with 4-(phenoxy)-2-[N-[(1,1-dimethylethoxy)carbonyl]-N-methylamino]-4-oxobutanoic acid Rapamycin-31,42-diester with 4-(phenylmethoxy)-3-[N-[(methoxy)carbonyl]-N-methylamino]-4-oxobutanoic acid EXAMPLE 6 Rapamycin-42-ester with 5-(1,1-dimethylethoxy)-2-[[(1,1-dimethylethoxy)carbonyl]amino]-5-oxopentanoic acid The title compound (1.14 g, 20.6%) was separated from the 31,42-diester as described in Example 5 and isolated as the quarter hydrate/mono-ethyl acetate solvate. HPLC analysis showed that the monoester is a 11.5:1 mixture of two conformers. 1 H NMR (CDCl 3 , 400 MHz): δ1.425 (m, 18H, COOBu t ), 1.643 (s, 3H, CH 3 C═C), 1.737 (s, 3H, CH 3 C═C), 3.13 (s, 3H, CH 3 O), 3.32 (s, 3H, CH 3 O), 3.36 (s, 3H, CH 3 O), 4.17 (d, 1H, CHOH), 4.71 (M, 1H, 42-CHO), 4.785 (s, 1H, OH); High Resolution MS (neg. ion FAB): Calc. for C 65 H 102 N 2 O 18 1198.7127, measured mass 1198.7077. Anal. Calcd for C 65 H 102 N 2 O 18 .CH 3 COOEt.0.25 H 2 O: C, 64.13, H, 8.60; N, 2.17; Found: C, 64.18; H, 8.52: N, 2.01. The following representative compounds can be prepared from rapamycin and the appropriately terminally-N-substituted amino diacid monoester by employing the method used to prepare the title compound in Example 6. Rapamycin-42-ester with 6-(phenylmethoxy)-2-[[fluorenylmethoxy)carbonyl]-amino]-6-oxohexanoic acid Rapamycin-42-ester with 6-(4'-methylphenoxy)-3-[[(phenylmethoxy)carbonyl]-amino-6-oxohexanoic acid Rapamycin-42-iester with 6-(ethoxy)-4-[[(phenoxy)carbonyl]amino]-6-oxo-hexanoic acid Rapamycin-42-ester with 6-(methoxy)-5-[[(ethoxy)carbonyl]amino]-6-oxo-hexanoic acid Rapamycin-42-ester with 4-(phenoxy)-2-[N-[(1,1-dimethylethoxy)carbonyl]-N-methylamino]-4-oxobutanoic acid Rapamycin-42-ester with 4-(phenylmethoxy)-3-[N-[(methoxy)carbonyl]-N-methylamino]-4-oxobutanoic acid EXAMPLE 7 Rapamycin-31,42-diester with 2-[[(1,1-dimethylethoxy)carbonyl]amino]-4-oxo-4-(phenylmethoxy) butanoic acid Under anhydrous conditions, 295 mg (1.21 mmol) of 2,4,6 trichlorobenzoyl chloride was added to a solution of 391 mg (1.21 mmol) of N.sup.α -Boc-L-aspartic acid-β-benzyl ester and 170 μL (1.21 mmol) of Et 3 N in 1 mL of THF at room temperature. After stirring for 30 minutes, 500 mg (0.55 mmol) of rapamycin and 295 mg (2.42 mmol) of dimethylaminopyridine was added and the reaction was left to stir overnight. The reaction mixture was then filtered and the filtrate concentrated in vacuo. Pure product (200 mg, 25%) was obtained by preparative HPLC (5 cm column, 40% ethyl acetate-hexane). The product was isolated as the heptahydrate. 1 H NMR (CDCl 3 , 400 MHz) δ7.347 (s, 10H, Ar), 6.223, 5.126 (s, 4H, CH 2 Ph), 4.698 (m, 1H, CH--CO 2 ), 4.587 (m, 2H, NH), 3.353 (s, 3H, CH 3 O), 3.337 (s, 3H, CH 3 O), 3.301 (s, 3H, CH 3 O), 2.775 (m, 4H, CH 2 CO 2 ); IR (KBr) 3420 (OH), 2935 (CH), 2920 (CH), 1730 (C═O), 1650, 1500, 1455, 1370, 1170 cm -1 ; MS (neg. ion FAB) 1523 (M - ), 1433, 297, 248, 205, 148, 44, 25 (100). Anal. Calcd for C 83 H 117 N 3 O 23 .7H 2 O C, 60.40; H, 7.09; N, 2.54; Found: C, 60.54; H, 7.28; N, 2.56. EXAMPLE 8 Rapamycin-31,42-diester with 3-[[(1,1-dimethylethoxy)carbonyl]amino]-4-oxo-4-(phenylmethoxy) butanoic acid Under anhydrous conditions, 532 mg (2.18 mmol) of 2,4,6 trichlorobenzoyl chloride in 1 mL THF was added to a solution of 704 mg (2.18 mmol) of N.sup.α -Boc-L-aspartic acid-α-benzyl ester and 303 μL (2.18 mmol) of Et 3 N in 5 mL of THF at room temperature. After stirring for 20 minutes, the reaction mixture was filtered over sintered glass, and the precipitate was washed with THF. The filtrate was concentrated in vacuo to give a thick oil. The oil was dissolved in 5 mL of benzene and 1.00 g (1.09 mmol) of rapamycin and 532 mg (4.36 mmol) of dimethylaminopyridine in 1 mL of benzene was added dropwise. The reaction was stirred for 2 hr, poured into ethyl acetate, and washed consecutively with 0.5N HCl and brine. The solution was dried over sodium sulfate, decanted, concentrated in vacuo to give a white foamy solid, which was purified via flash chromatography on a 60 mm×100 mm silica column (20-40% ethyl acetate/hexane as eluant) to give 532 mg (33%) of the title compound which was isolated as the hydrate. 1 H NMR (CDCl 3 , 400 MHz) δ7.362 (s, 10H, Ar), 5.193 (s, 4H, CH 2 Ph), 4.596 (m, 1H, CH--CO 2 ), 4.586 (m, 2H, NH), 3.336 (s, 3H, CH 3 O), 3.306 (s, 3H, CH 3 O), 3.145 (s, 3H, CH 3 O); IR (KBr) 3410 (OH), 2950 (CH), 2920 (CH), 1735 (C═O), 1710 (C═O), 1640, 1490, 1445, 1350, 1150 cm -1 ; MS (neg. ion FAB) 1524 (M - ), 1434, 297, 248, 232, 214, 205, 167, 148, 42 (100), 26. Anal. Calcd for C 83 H 117 N 3 O 23 .H 2 O: C, 65.38; H, 7.73; N, 2.76; Found: C, 64.85; H, 7.67; N, 2.56. EXAMPLE 9 Rapamycin-42-ester with 3-[[(1,1-dimethylethoxy)carbonyl]amino]-4-oxo-4-(phenylmethoxy) butanoic acid The title compound (374 mg, 23%) was prepared by the method described in the previous Example and separated from the compound described in the previous Example by flash chromatography (20-40% ethyl acetate/hexane as the eluant) and isolated as the sesquihydrate. 1 H NMR (CDCl 3 , 400 MHz) δ7.356 (s, 5H, Ar), 5.185 (s, 2H, CH 2 Ph), 4.635 (m, 1H, CH-CO 2 ), 4.582 (m, 1H, NH), 3.330 (s, 6H, CH 3 O), 3.135 (s, 3H, CH 3 O); IR (KBr) 3410 (OH), 2950 (CH), 2920 (CH), 1735 (C═O), 1710 (C═O), 1640, 1490, 1445, 1350, 1150 cm -1 ; MS (neg. ion FAB) 1218 (M - ), 1127, 590, 168, 42, 25, 17 (100). Anal. Calcd for C 67 H 98 N 2 O 18 . 1.5 H 2 O: C, 63.64; H, 8.21; N, 2.22; Found: C, 63.64; H, 7.51; N, 2.13. EXAMPLE 10 Rapamycin-42-ester with 5-(1,1-dimethyloxy)-4-[[(1,1-dimethylethoxy)carbonyl]amino]-5-oxopentanoic acid Under anhydrous conditions, an ice cold solution of rapamycin (4 g, 4.37 mmole) and L-glutamic acid N.sup.α -Boc-α-tert-butylester (4.9 g, 16.1 mmole) in 40 mL of anhydrous dichloromethane was treated with dicyclohexylcarbodiimide (1.8 g, 8.7 mmole) followed by 4-dimethylamino pyridine (1 g, 8.7 mmole). After stirring overnight at ambient temperature, the precipitated solid was collected and washed with dichloromethane. The combined filtrates were concentrated in vacuo to give 9 g of an amorphous amber solid. The crude product was purified by flash chromatography (on silica Merck 60, gradient elution with hexane-ethylacetate from 2:1 to 3:2, v/v) to provide 1.35 g (25.7%) of the title compound along with the 31,42-diester of Example 11. HPLC analysis showed that the monoester is a 7.5:1 mixture of two conformers. 1 H NMR (CDCl 3 , 400 MHz): δ1.43 (s, 9H, COOBu t ) and 1.46 (s, 9H, COOBu t ), 1.65 (s, 3H, CH 3 C═C), 1.75 (s, 3H, CH 3 C═C), 3.14 (s, 3H, CH 3 O), 3.34 (s, 3H, CH 3 O), 3.38 (s, 3H, CH 3 O), 4.18 (d, 1H, CH-OH), 4.65 (m, 1H, 42-CHO), 4.80 (s, 1H, OH); High Res. MS (neg. ion FAB): Calc. for C 65 H 102 N 2 O 18 : 1198.7126, measured mass 1198.7135. Anal. Calcd for C 65 H 102 N 2 O 18 : C, 65.09; H, 8.57; N, 2.34; Found C, 65.04; H, 8.33; N, 2.64. EXAMPLE 11 Rapamycin-31,42-diester with 5-(1,1-dimethylethoxy)-4-[[(1,1-dimethylethoxy)-carbonyl]-amino]-5-oxopentanoic acid The title compound was prepared (0.83 g, 12.8%) along with the 42-monoester as described in Example 10. HPLC analysis showed that the diester is a 7.7:1 mixture of two conformers. 1 H NMR (CDCl 3 , 400 MHz): δ1.43 (s, 18H, COOBu t ), 1.46 (s, 18H, COOBu t ), 1.659 (s, 3H, CH 3 C═C), 1.759 (s, 3H, CH 3 C═C), 3.14 (s, 3H, CH 3 O), 3.34 (s, 3H, CH 3 O), 3.38 (s, 3H, CH 3 O), 4.66 (m, 1H, 42-CHO), 4.72 (s, 1H, OH); High Res. MS (neg. ion FAB): Calcd for C 79 H 125 N 3 O 23 : 1483.8704, measured mass 1483.8636. Anal. Calcd for C 79 H 125 N 3 O 23 : C, 63.90; H, 8.49; N, 2.83; Found: C, 63.68; H, 8.60; N, 3.20. EXAMPLE 12 Rapamycin-42-ester with N.sup.α, N.sup.ε -bis[(1,1-dimethylethoxy)carbonyl]-L-lysine Under anhydrous conditions, a solution of rapamycin (3 g, 3.28 mmole) and N.sup.α, N.sup.ε -bis-Boc-L-lysine (4.5 g, 13 mmole) in 40 mL of anhydrous dichloromethane was treated with dicyclohexylcarbodiimide (1.35 g, 6.56 mmole) followed by 4-dimethylaminopyridine (0.8 g, 6.56 m mole). After stirring overnight at ambient temperature, the precipitated solid was collected and washed with dichloromethane. The combined filtrates were concentrated in vacuo to give an amorphous amber solid. Flash chromatography of the crude product (on silica Merck 60, elution with hexane-ethylacetate 1:1 v/v) gave partially purified title compound. Pure product (0.8 g, 19.6%) was obtained by preparative HPLC (Waters Prep 500, silica gel, hexane-ethylacetate 3:2 v/v, flow rate 250 mL/min). HPLC analysis showed that the monoester is a 9:1 mixture of two conformers. 1 H NMR (CDCl 3 , 400 MHz): δ1.438 (m, 9H, COOBu t ), 1.455 (s, 9H, COOBu t ), 1.652 (s, 3H, CH 3 C═C), 1.752 (s, 3H, CH 3 C═C), 3.14 (s, 3H, CH 3 O), 3.33(s, 3H, CH 3 O), 3.37 (s, 3H, CH 3 O), 4.18 (d, 1H, CHOH), 4.72 (m, 1H, 42-CHO), 4.79 (s, 1H, OH); High Res. MS (neg. ion FAB): Calcd for C 67 H 107 N 3 O 18 : 1241.7549, measured mass 1241.7604. Anal. Calcd for C 67 H 107 N 3 O 18 : C, 64.76; H, 8.68; N, 3.38; Found: C, 64.58; H, 9.01; N, 3.10. EXAMPLE 13 Rapamycin-31,42-diester with N.sup.α, N.sup.ε bis [(1,1-dimethylethoxy)carbonyl]-L-lysine Under a nitrogen atmosphere, a solution of N.sup.α, N.sup.ε bis-Boc-L-lysine (1.038 g, 3 mmole) and triethylamine (0.42 mL, 3 mmmole) in 10 mL of anhydrous THF was treated in one portion with 2,4,6-trichlorobenzoyl chloride (0.73 g, 3 mmole). After stirring for 20 minutes at ambient temperature, the precipitated solid was collected and the filtrate was concentrated in vacuo. The resulting mixed anhydride was dissolved in 5 mL of benzeme and added to a stirred solution of rapamycin (1 g, 1.09 mmole) containing 4-dimethylamino pyridine (0.59 g, 4.8 mmole) in 10 mL of benzene. After stirring at ambient temperature overnight, the precipitated solid was collected and the filtrate was evaporated to dryness (yellow foam). The crude product was purified by flash chromatography (on silica Merck 60, elution with hexane-ethylacetate 1:1) to provide title compound (1.15 g, 67%). HPLC analysis shows that the diester is a 9:1 mixture of two conformers. 1 H NMR (CDCl 3 , 400 MHz): δ1.426 (m, 9H, COOBu t ), 1.438 (s, 9H, COOBu t ), 1.443 (s, 9H, COOBu t ), 1.446 (s, 9H, COOBu t ), 3.141 (s, 3H, CH 3 O), 3.36 (s, 3H, CH 3 O), 3.378 (s, 3H, CH 3 O), 4.68-4.76 (m, 2H, OH and 42-CHO); High res. MS (neg. ion FAB): Calcd. for C 83 H 135 N 5 O 23 1569.9526, measured mass 1569.9537. Anal. Calcd. for C 83 H 135 N 5 O 23 : C, 63.46; H, 8.66; N, 4.46; Found: C, 63.06; H, 8.84; N, 4.09.

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (6)

    Publication numberPublication dateAssigneeTitle
    US-3929992-ADecember 30, 1975Ayerst Mckenna & HarrisonRapamycin and process of preparation
    US-3993749-ANovember 23, 1976Ayerst Mckenna And Harrison Ltd.Rapamycin and process of preparation
    US-4316885-AFebruary 23, 1982Ayerst, Mckenna And Harrison, Inc.Acyl derivatives of rapamycin
    US-4401653-AAugust 30, 1983Ayerst, Mckenna & Harrison Inc.Combination of rapamycin and picibanil for the treatment of tumors
    US-4650803-AMarch 17, 1987University Of KansasProdrugs of rapamycin
    US-4885171-ADecember 05, 1989American Home Products CorporationUse of rapamycin in treatment of certain tumors

NO-Patent Citations (8)

    Title
    Can. J. Physiol. Pharmacol. 55, 48 (1977).
    FASEB 3, 3411 (1989).
    FASEB 3, 5256 (1989).
    Immunology, C. V. Moseby Co., pp. 12.8 12.11 (1989).
    J. Antibiot. 28, 721 726 (1975).
    J. Antibiot. 28, 727 732 (1975).
    J. Antibiot. 31, 539 545 (1978).
    Lancet, 1183 (1978).

Cited By (160)

    Publication numberPublication dateAssigneeTitle
    WO-2006090291-A2August 31, 2006Fondazione Centro San Raffaele Del Monte Tabor, Fondazione TelethonMethod for expanding cd4+ cd25+ t regulatory cells
    US-5508290-AApril 16, 1996American Home Products CorporationHindered N-oxide esters of rapamycin
    US-7625726-B2December 01, 2009WyethProcess for preparing rapamycin 42-esters and FK-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies
    US-5486523-AJanuary 23, 1996American Home Products CorporationCarbamates of rapamycin
    US-6328970-B1December 11, 2001American Home Products CorporationRapamycin position 27 conjugates
    US-2005239178-A1October 27, 2005WyethLabeling of rapamycin using rapamycin-specific methylases
    US-8414525-B2April 09, 2013Lutonix, Inc.Drug releasing coatings for medical devices
    US-7279561-B1October 09, 2007WyethAnti-rapamycin monoclonal antibodies
    WO-2013013708-A1January 31, 2013Fundació Institut D'investigació Biomèdica De BellvitgeTreatment of acute rejection in renal transplant
    US-7445916-B2November 04, 2008WyethProcess for preparing rapamycin 42-esters and FK-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies
    US-9248220-B2February 02, 2016Lutonix, Inc.Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
    US-5256790-AOctober 26, 1993American Home Products Corporation27-hydroxyrapamycin and derivatives thereof
    US-5530121-AJune 25, 1996American Home Products CorporationCarbamates of rapamycin
    US-5677295-AOctober 14, 1997American Home ProdRapamycin 42-oximes and hydroxylamines
    US-8465724-B2June 18, 2013Endocyte, Inc.Multi-drug ligand conjugates
    US-6635745-B2October 21, 2003Novartis AgRapamycin assay
    US-5508399-AApril 16, 1996American Home Products CorporationCarbamates of rapamycin
    US-2009029426-A1January 29, 2009WyethProcess for preparing rapamycin 42-esters and fk-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies
    US-8414909-B2April 09, 2013Lutonix, Inc.Drug releasing coatings for medical devices
    US-5489595-AFebruary 06, 1996American Home Products CorporationCarbamates of rapamycin
    US-6399626-B1June 04, 2002WyethHydroxyesters of 7-desmethylrapamycin
    US-9402935-B2August 02, 2016Lutonix, Inc.Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
    US-5484790-AJanuary 16, 1996American Home Products CorporationCarbamates of rapamycin
    US-5362718-ANovember 08, 1994American Home Products CorporationRapamycin hydroxyesters
    US-5559112-ASeptember 24, 1996American Home Products CorporationCarbamates of rapamycin
    US-6670355-B2December 30, 2003WyethMethod of treating cardiovascular disease
    US-5541191-AJuly 30, 1996American Home Products CorporationRapamycin amidino carbamates
    WO-2017029391-A1February 23, 2017INSERM (Institut National de la Santé et de la Recherche Médicale), Université D'aix Marseille, Institut Jean Paoli & Irene Calmettes, Centre National De La Recherche Scientifique (Cnrs)Nouvelle méthode de traitement du cancer
    US-5559122-ASeptember 24, 1996American Home Products CorporationHindered N-oxide esters of rapamycin
    US-5480989-AJanuary 02, 1996American Home Products CorporationCarbamates of rapamycin
    US-5455249-AOctober 03, 1995Skotnicki; Jerauld S., Smith; Andri L.Phosphorylcarbamates of rapamycin and oxime derivatives thereof
    US-9005161-B2April 14, 2015Lutonix, Inc.Drug releasing coatings for medical devices
    US-9545396-B2January 17, 2017Targeted Therapeutics, LlcMethod and pharmaceutical composition for inhibiting PI3K/AKT/mTOR signaling pathway
    US-5349060-ASeptember 20, 1994American Home Products CorporationRapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents
    US-5252579-AOctober 12, 1993American Home Products CorporationMacrocyclic immunomodulators
    US-8998846-B2April 07, 2015Lutonix, Inc.Drug releasing coatings for balloon catheters
    US-9750728-B2September 05, 2017Targeted Therapeutics, LlcMethod and pharmaceutical composition for inhibiting PI3K/AKT/mTOR signaling pathway
    US-5387680-AFebruary 07, 1995American Home Products CorporationC-22 ring stabilized rapamycin derivatives
    US-5488054-AJanuary 30, 1996American Home Products CorporationCarbamates of Rapamycin
    US-6331547-B1December 18, 2001American Home Products CorporationWater soluble SDZ RAD esters
    US-5955457-ASeptember 21, 1999American Home Products CorporationWater soluble rapamycin esters
    US-5532355-AJuly 02, 1996American Home Products CorporationCarbamates of rapamycin
    US-9555139-B2January 31, 2017Endocyte, Inc.Binding ligand linked drug delivery conjugates of tubulysins
    US-9505747-B2November 29, 2016Endocyte, Inc.Processes for preparing tubulysin derivatives and conjugates thereof
    US-6399625-B1June 04, 2002Wyeth1-oxorapamycins
    US-6709873-B1March 23, 2004Isodiagnostika Inc.Method for production of antibodies to specific sites of rapamycin
    US-8044200-B2October 25, 2011Endocyte, Inc.Synthesis and purification of pteroic acid and conjugates thereof
    US-5302584-AApril 12, 1994American Home Products CorporationCarbamates of rapamycin
    US-9289537-B2March 22, 2016Lutonix, Inc.Medical device rapid drug releasing coatings comprising oils, fatty acids and/or lipids
    US-9101609-B2August 11, 2015Emergent Product Development Seattle, LlcCD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
    US-5563145-AOctober 08, 1996American Home Products CorporationRapamycin 42-oximes and hydroxylamines
    US-RE44768-EFebruary 18, 2014Wyeth LlcRapamycin hydroxyesters
    US-2005234087-A1October 20, 2005WyethProcess for preparing rapamycin 42-esters and FK-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies
    US-9023371-B2May 05, 2015Lutonix, Inc.Drug releasing coatings for medical devices
    US-8425459-B2April 23, 2013Lutonix, Inc.Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
    US-2008207625-A1August 28, 2008Endocyte, Inc.Synthesis and Purification of Pteroic Acid and Conjugates Thereof
    US-5559119-ASeptember 24, 1996American Home Products CorporationCarbamates of rapamycin
    US-5346893-ASeptember 13, 1994American Home Products CorporationRapamycin 42-sulfonates and 42-(N-carbalkoxy) sulfamates useful as immunosuppressive agents
    US-6440991-B1August 27, 2002WyethEthers of 7-desmethlrapamycin
    US-5516780-AMay 14, 1996American Home Products CorporationCarbamates of rapamycin
    US-6015809-AJanuary 18, 2000American Home Products CorporationPhotocyclized rapamycin
    US-2006121545-A1June 08, 2006WyethRapamycin conjugates and antibodies
    US-9877965-B2January 30, 2018Endocyte, Inc.Vitamin receptor drug delivery conjugates for treating inflammation
    US-5385910-AJanuary 31, 1995American Home Products CorporationGem-distributed esters of rapamycin
    US-9770576-B2September 26, 2017Lutonix, Inc.Methods and apparatuses for coating balloon catheters
    WO-2012149014-A1November 01, 2012OSI Pharmaceuticals, LLC, Aveo Pharmaceuticals, Inc.Utilisation de signatures de gènes de tem dans la découverte de médicaments contre le cancer, diagnostics et traitement du cancer
    US-8932561-B2January 13, 2015Lutonix, Inc.Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
    US-9138484-B2September 22, 2015Endocyte, Inc.Conjugates containing hydrophilic spacer linkers
    US-5525610-AJune 11, 1996American Home Products Corporation42-Epi-rapamycin and pharmaceutical compositions thereof
    US-8562974-B2October 22, 2013Fondazione Telethon, Ospedale San Raffaele S.R.L.Method for expanding Cd4+ Cd25+ T regulator cells
    US-5530007-AJune 25, 1996American Home Products CorporationCarbamates of rapamycin
    US-8105568-B2January 31, 2012Endocyte, Inc.Vitamin receptor binding drug delivery conjugates
    US-9757351-B2September 12, 2017Lutonix, Inc.Medical device rapid drug releasing coatings comprising oils, fatty acids and/or lipids
    US-5508286-AApril 16, 1996American Home Products CorporationRapamycin amidino carbamates
    US-5480988-AJanuary 02, 1996American Home Products CorporationCarbamates of rapamycin
    US-5559227-ASeptember 24, 1996American Home Products CorporationCarbamates of rapaycin
    US-6432973-B1August 13, 2002WyethWater soluble rapamycin esters
    US-9289539-B2March 22, 2016Lutonix, Inc.Drug releasing coatings for medical devices
    US-5302600-AApril 12, 1994American Home Products Corporation27-hydroxyrapamycin and derivatives thereof
    US-5484791-AJanuary 16, 1996American Home Products CorporationCarbamates of rapamycin
    US-5780462-AJuly 14, 1998American Home Products CorporationWater soluble rapamycin esters
    US-5463048-AOctober 31, 1995American Home Products CorporationRapamycin amidino carbamates
    US-7897733-B2March 01, 2011Pfizer, Inc.Rapamycin conjugates and antibodies
    US-6277983-B1August 21, 2001American Home Products CorporationRegioselective synthesis of rapamycin derivatives
    US-2006210604-A1September 21, 2006Eric Dadey, Lindemann Christopher M, Warren Stephen L, Norton Richard LOcular delivery of polymeric delivery formulations
    US-9700704-B2July 11, 2017Lutonix, Inc.Drug releasing coatings for balloon catheters
    US-9662402-B2May 30, 2017Endocyte, Inc.Drug delivery conjugates containing unnatural amino acids and methods for using
    US-5504204-AApril 02, 1996American Home Products CorporationCarbamates of rapamycin
    US-5521194-AMay 28, 1996American Home Products CorporationHindered N-oxide esters of rapamycin
    US-5559120-ASeptember 24, 1996American Home Products CorporationCarbamates of rapamycin
    US-2008014614-A1January 17, 2008WyethLabeling of rapamycin using rapamycin-specific methylases
    US-5389639-AFebruary 14, 1995American Home Products CompanyAmino alkanoic esters of rapamycin
    US-9737640-B2August 22, 2017Lutonix, Inc.Drug releasing coatings for medical devices
    US-9737691-B2August 22, 2017Lutonix, Inc.Drug releasing coatings for balloon catheters
    US-9033919-B2May 19, 2015Lutonix, Inc.Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
    US-2011060265-A1March 10, 2011Wyeth LlcImplantable shunt or catheter enabling gradual delivery of therapeutic agents
    US-5550133-AAugust 27, 1996American Home Products CorporationCarbamates of rapamycin
    US-8414526-B2April 09, 2013Lutonix, Inc.Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
    US-5446048-AAugust 29, 1995American Home Products CorporationRapamycin oximes
    US-5373014-ADecember 13, 1994American Home Products CorporationRapamycin oximes
    US-8404300-B2March 26, 2013Lutonix, Inc.Drug releasing coatings for medical devices
    US-5385909-AJanuary 31, 1995American Home Products CorporationHeterocyclic esters of rapamycin
    US-6511986-B2January 28, 2003WyethMethod of treating estrogen receptor positive carcinoma
    US-5637590-AJune 10, 1997American Home Products CorporationRapamycin amidino carbamates
    WO-2014048071-A1April 03, 2014Duan Lei, Levenson Victor, Ying GuoguangProcédé et composition pharmaceutique pour inhiber la voie de signalisation pi3k/akt/mtor
    US-9694111-B2July 04, 2017Lutonix, Inc.Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
    US-8039599-B1October 18, 2011Novartis AgRapamycin assay
    US-2008248052-A1October 09, 2008Iontcho Radoslavov Vlahov, Christopher Paul LeamoMulti-Drug Ligand Conjugates
    US-9764065-B2September 19, 2017Lutonix, Inc.Drug releasing coatings for medical devices
    US-5491231-AFebruary 13, 1996American Home Products CorporationHindered N-oxide esters of rapamycin
    US-5489680-AFebruary 06, 1996American Home Products CorporationCarbamates of rapamycin
    US-8414910-B2April 09, 2013Lutonix, Inc.Drug releasing coatings for medical devices
    US-7279562-B2October 09, 2007WyethRapamycin conjugates
    US-8853366-B2October 07, 2014Emergent Product Development Seattle, LlcBinding domain-immunoglobulin fusion proteins
    US-5504091-AApril 02, 1996American Home Products CorporationBiotin esters of rapamycin
    US-5378696-AJanuary 03, 1995American Home Products CorporationRapamycin esters
    US-5486522-AJanuary 23, 1996American Home Products CorporationCarbamates of rapamycin
    US-5391730-AFebruary 21, 1995American Home Products CorporationPhosphorylcarbamates of rapamycin and oxime derivatives thereof
    US-5434260-AJuly 18, 1995American Home Products CorporationCarbamates of rapamycin
    US-5508285-AApril 16, 1996American Home Products CorporationHindered N-oxide esters of rapamycin
    US-6541612-B2April 01, 2003WyethMonoclonal antibodies obtained using rapamycin position 27 conjugates as an immunogen
    US-8998847-B2April 07, 2015Lutonix, Inc.Drug releasing coatings for medical devices
    US-5385908-AJanuary 31, 1995American Home Products CorporationHindered esters of rapamycin
    US-5378836-AJanuary 03, 1995American Home Products CorporationRapamycin oximes and hydrazones
    WO-9402137-A1February 03, 1994Smithkline Beecham CorporationDerives de rapamycine
    US-9283358-B2March 15, 2016Lutonix, Inc.Drug releasing coatings for medical devices
    US-9283211-B1March 15, 2016Rapamycin Holdings, LlcOral rapamycin preparation and use for stomatitis
    US-6117863-ASeptember 12, 2000American Home Products CorporationPhotocyclized rapamycin
    US-9314598-B2April 19, 2016Lutonix, Inc.Drug releasing coatings for balloon catheters
    US-8403910-B2March 26, 2013Lutonix, Inc.Drug releasing coatings for medical devices
    US-9314552-B2April 19, 2016Lutonix, Inc.Drug releasing coatings for medical devices
    US-8430055-B2April 30, 2013Lutonix, Inc.Methods and apparatuses for coating balloon catheters
    US-5661156-AAugust 26, 1997Smithkline Beecham CorporationRapamycin derivatives
    US-8366660-B2February 05, 2013Lutonix, Inc.Drug releasing coatings for medical devices
    WO-2012171882-A1December 20, 2012Hans-Dieter Volk, Schmueck Michael, Petra ReinkeAntigen-specific central-memory t cell preparations having high cd4+ fraction
    US-9757544-B2September 12, 2017Lutonix, Inc.Drug releasing coatings for medical devices
    EP-2583678-A2April 24, 2013Novartis Vaccines and Diagnostics, Inc.Immunstimulatoren kleiner Moleküle und Assays für deren Nachweis
    US-2008304101-A1December 11, 2008Naoko SasaseServer and printer introducing method under thin client environment
    WO-2014059295-A1April 17, 2014The Board Of Regents Of The University Of Texas SystemUtilisation d'inhibiteurs mtor pour traiter le déficit cognitif vasculaire
    US-5486524-AJanuary 23, 1996American Home Products CorporationCarbamates of rapamycin
    US-5922730-AJuly 13, 1999American Home Products CorporationAlkylated rapamycin derivatives
    WO-2011109833-A2September 09, 2011President And Fellows Of Harvard CollegeInduced dendritic cell compositions and uses thereof
    US-9700544-B2July 11, 2017Neal K Vail, Dana M VaughnOral rapamycin nanoparticle preparations
    US-RE37421-EOctober 23, 2001Smithkline Beecham CorporationRapamycin derivatives
    US-5541192-AJuly 30, 1996American Home Products CorporationRapamycin amidino carbamates
    EP-2407473-A2January 18, 2012ARIAD Pharmaceuticals, IncVerfahren zur Herstellung von phosphorhaltigen Verbindungen
    US-9180485-B2November 10, 2015Lutonix, Inc.Methods and apparatuses for coating balloon catheters
    WO-2010056754-A2May 20, 2010The Board Regents Of The University Of Texas SystemInhibition of mammalian target of rapamycin
    WO-2014068070-A1May 08, 2014INSERM (Institut National de la Santé et de la Recherche Médicale)Methods for preventing antiphospholipid syndrome (aps)
    US-8313763-B2November 20, 2012Tolmar Therapeutics, Inc.Sustained delivery formulations of rapamycin compounds
    EP-2532740-A1December 12, 2012Michael Schmück, Petra Reinke, Hans-Dieter VolkPréparations de lymphocytes T à mémoire centrale CD4+ et CD8+ spécifiques aux antigènes pour thérapie de lymphocyte T adoptif
    US-9090563-B2July 28, 2015Endocyte, Inc.Bivalent linkers and conjugates thereof
    US-2007280992-A1December 06, 2007Qlt Usa, Inc.Sustained delivery formulations of rapamycin compounds
    US-2008279826-A1November 13, 2008Fondazione Centro San Rafaele Del Monte Tabor, Fondazione TelethonMethod for Expanding Cd4+ Cd25+ T Regulator Cells
    US-8039600-B2October 18, 2011Novartis AgRapamycin assay
    US-9550734-B2January 24, 2017Endocyte, Inc.Bivalent linkers and conjugates thereof
    US-8765096-B2July 01, 2014Endocyte, IncMethods and compositions for treating and diagnosing kidney disease
    US-RE40596-EDecember 02, 2008Novartis AgRapamycin assay
    US-8366662-B2February 05, 2013Lutonix, Inc.Drug releasing coatings for medical devices
    WO-2011134899-A1November 03, 2011Roche Glycart AgCombination therapy of an afucosylated cd20 antibody with a mtor inhibitor